Impact of HDL on adipose tissue metabolism and adiponectin expression

Atherosclerosis

Volumn 210, Issue 2, 2010, Pages 438-444

  Van Linthout, Sophie ^a   Foryst Ludwig, Anna ^a   Spillmann, Frank ^a   Peng, Jun ^a   Feng, Yingmei ^b   Meloni, Marco ^a   Van Craeyveld, Eline ^b   Kintscher, Ulrich ^a   Schultheiss, Heinz Peter ^a   De Geest, Bart ^b   Tschöpe, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adiponectin; Apo A I; HDL cholesterol

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; CD36 ANTIGEN; FATTY ACID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPOLYSACCHARIDE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRIACYLGLYCEROL;

ABDOMINAL FAT; ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; DOWN REGULATION; GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; LIPID ANALYSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE METABOLISM; WESTERN BLOTTING;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; APOLIPOPROTEIN A-I; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; HUMANS; LIPOPOLYSACCHARIDES; LIPOPROTEINS, HDL; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL;

EID: 77952474019     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.01.001     Document Type: Article

References (43)

1. Ouchi N., Ohishi M., Kihara S., et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42:231-234.
2. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
3. Van Linthout S., Spillmann F., Riad A., et al. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation 2008, 117:1563-1573.
4. Van Linthout S., Spillmann F., Lorenz M., et al. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 2009, 53:682-687.
5. Zietz B., Herfarth H., Paul G., et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003, 545:103-104.
6. Schulze M.B., Rimm E.B., Shai I., et al. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004, 27:1680-1687.
7. Cnop M., Havel P.J., Utzschneider K.M., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003, 46:459-469.
8. Cote M., Mauriege P., Bergeron J., et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005, 90:1434-1439.
9. Verges B., Petit J.M., Duvillard L., et al. Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 2006, 26:1364-1369.
10. von Eynatten M., Hamann A., Twardella D., et al. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 2006, 52:853-859.
11. Tschritter O., Fritsche A., Thamer C., et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003, 52:239-243.
12. de Souza J.A., Vindis C., Hansel B., et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 2008, 197:84-94.
13. Catalano G., Julia Z., Frisdal E., et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009, 29:268-275.
14. Baratta R., Amato S., Degano C., et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 2004, 89:2665-2671.
15. Fong B.S., Rodrigues P.O., Salter A.M., et al. Characterization of high density lipoprotein binding to human adipocyte plasma membranes. J Clin Invest 1985, 75:1804-1812.
16. Wu A., Hinds C.J., Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 2004, 21:210-221.
17. Tsuchihashi H., Yamamoto H., Maeda K., et al. Circulating concentrations of adiponectin, an endogenous lipopolysaccharide neutralizing protein, decrease in rats with polymicrobial sepsis. J Surg Res 2006, 134:348-353.
18. Van Linthout S., Collen D., De Geest B. Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein a-I. Hum Gene Ther 2002, 13:829-840.
19. Van Linthout S., Lusky M., Collen D., et al. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector. Gene Ther 2002, 9:1520-1528.
20. De Geest B., Zhao Z., Collen D., et al. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation 1997, 96:4349-4356.
21. De Geest B., Van Linthout S., Collen D. Sustained expression of human apo A-I following adenoviral gene transfer in mice. Gene Ther 2001, 8:121-127.
22. Jacobs F., Van Craeyveld E., Feng Y., et al. Adenoviral low density lipoprotein receptor attenuates progression of atherosclerosis and decreases tissue cholesterol levels in a murine model of familial hypercholesterolemia. Atherosclerosis 2008, 201:289-297.
23. Schupp M., Clemenz M., Gineste R., et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005, 54:3442-3452.
24. Penfornis P., Marette A. Inducible nitric oxide synthase modulates lipolysis in adipocytes. J Lipid Res 2005, 46:135-142.
25. De Geest B., Snoeys J., Van Linthout S., et al. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum Gene Ther 2005, 16:1439-1451.
26. Pereira R.I., Draznin B. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway leads to decreased insulin-stimulated adiponectin secretion from 3T3-L1 adipocytes. Metabolism 2005, 54:1636-1643.
27. Cong L., Chen K., Li J., et al. Regulation of adiponectin and leptin secretion and expression by insulin through a PI3K-PDE3B dependent mechanism in rat primary adipocytes. Biochem J 2007, 403:519-525.
28. Guha M., Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 2002, 277:32124-32132.
29. Schabbauer G., Tencati M., Pedersen B., et al. PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Arterioscler Thromb Vasc Biol 2004, 24:1963-1969.
30. de Haas C.J., Poppelier M.J., van Kessel K.P., et al. Serum amyloid P component prevents high-density lipoprotein-mediated neutralization of lipopolysaccharide. Infect Immun 2000, 68:4954-4960.
31. Whiteman E.L., Cho H., Birnbaum M.J. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 2002, 13:444-451.
32. Phan J., Peterfy M., Reue K. Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro. J Biol Chem 2004, 279:29558-29564.
33. Lu B., Lu Y., Moser A.H., et al. LPS and proinflammatory cytokines decrease lipin-1 in mouse adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2008, 295:E1502-E1509.
34. Chien J.Y., Jerng J.S., Yu C.J., et al. Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005, 33:1688-1693.
35. Mineo C., Shaul P.W. Role of high-density lipoprotein and scavenger receptor B type I in the promotion of endothelial repair. Trends Cardiovasc Med 2007, 17:156-161.
36. Feng Y., Jacobs F., Van Craeyveld E., et al. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008, 28:278-283.
37. Teruel T., Hernandez R., Lorenzo M. Ceramide mediates insulin resistance by tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 2001, 50:2563-2571.
38. Kern P.A., Di Gregorio G.B., Lu T., et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003, 52:1779-1785.
39. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
40. Berg A.H., Combs T.P., Du X., et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-953.
41. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
42. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
43. Gupta H., Dai L., Datta G., et al. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide. Circ Res 2005, 97:236-243.